以蛋白质-蛋白质相互作用为靶点的HIV抑制剂的研究进展  

The progress in the development of HIV inhibitors targeting protein-protein interactions

作　　者：汪昭 Desta SAMUEL 康东伟[1] 展鹏[1] 刘新泳[1] WANG Zhao;SAMUEL Desta;KANG Dong-wei;ZHAN Peng;LIU Xin-yong(Department of Medicinal Chemistry, Key Laboratory of Chemical Biology(Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China)

机构地区：[1]山东大学药学院药物化学研究所化学生物学教育部重点实验室,山东济南250012

出　　处：《药学学报》2019年第4期620-628,共9页Acta Pharmaceutica Sinica

基　　金：国家自然科学基金资助项目(81420108027;81573347);2017年山东省重点研发计划(2017CXGC1401)

摘　　要：蛋白质-蛋白质相互作用(protein-protein interaction, PPI)在人免疫缺陷病毒(human immunodeficiency virus, HIV)生命周期中的多个阶段发挥重要作用。针对这些相互作用特别是HIV与宿主细胞之间的相互作用为我们研发靶向于新结合位点和具有新作用机制的HIV抑制剂提供了新思路。因此本综述基于多种蛋白质-蛋白质相互作用的作用机制,结合具体研究实例阐述了该类抑制剂的最新研究进展。Protein-protein interaction (PPI) plays an important role in many steps of the human immunodeficiency virus (HIV) life cycle. Targeting these protein-protein interactions, especially the interaction between the virus with host cells, can provide new insights into the development of HIV inhibitors with novel mechanisms of action. Herein, we review the latest discoveries of PPI inhibitors based on the mechanisms of action of various protein-protein interactions with specific research examples.

关 键 词：艾滋病 HIV 蛋白质-蛋白质相互作用 抑制剂 

分 类 号：R916[医药卫生—药学]